Form 8-K - Current report:
SEC Accession No. 0001708599-24-000033
Filing Date
2024-12-26
Accepted
2024-12-23 19:50:58
Documents
14
Period of Report
2024-12-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ser-20241223.htm   iXBRL 8-K 31820
2 EX-10.1 serinade-stockpurchaseagre.htm EX-10.1 112822
  Complete submission text file 0001708599-24-000033.txt   377181

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ser-20241223.xsd EX-101.SCH 1800
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ser-20241223_lab.xml EX-101.LAB 54435
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ser-20241223_pre.xml EX-101.PRE 31811
16 EXTRACTED XBRL INSTANCE DOCUMENT ser-20241223_htm.xml XML 3207
Mailing Address 601 GENOME WAY SUITE 2001 HUNTSVILLE AL 35806
Business Address 601 GENOME WAY SUITE 2001 HUNTSVILLE AL 35806 (256) 327-9630
Serina Therapeutics, Inc. (Filer) CIK: 0001708599 (see all company filings)

EIN.: 821436829 | State of Incorp.: AL | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38519 | Film No.: 241575353
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)